Why indeed is the FDA requesting additional monoth
Post# of 148170
(Total Views: 668)
Posted On: 07/15/2020 1:01:57 AM
Why indeed is the FDA requesting additional monotherapy patient data.
That is the question.
I think the best answer is that the FDA is nervous about approving a higher dose than what was tested in phase 3.
This is most likely answer if the FDA has never done this before.
That is the question.
I think the best answer is that the FDA is nervous about approving a higher dose than what was tested in phase 3.
This is most likely answer if the FDA has never done this before.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼